These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 29336928)

  • 1. Tackling the recurrence of Clostridium difficile infection.
    Petrosillo N
    Med Mal Infect; 2018 Feb; 48(1):18-22. PubMed ID: 29336928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring ways to improve CDI outcomes.
    Galpérine T; Guery B;
    Med Mal Infect; 2018 Feb; 48(1):10-17. PubMed ID: 29336930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Best strategies in recurrent or persistent Clostridium difficile infection.
    Cocanour CS
    Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
    Kimura T; Snijder R; Sugitani T
    J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
    Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbiologic factors affecting Clostridium difficile recurrence.
    Chilton CH; Pickering DS; Freeman J
    Clin Microbiol Infect; 2018 May; 24(5):476-482. PubMed ID: 29208562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
    Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
    Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The host immune response to Clostridium difficile.
    Kelly CP; Kyne L
    J Med Microbiol; 2011 Aug; 60(Pt 8):1070-1079. PubMed ID: 21415200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
    Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent
    Song JH; Kim YS
    Gut Liver; 2019 Jan; 13(1):16-24. PubMed ID: 30400734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and treatment of
    Eliakim-Raz N; Bishara J
    Hum Vaccin Immunother; 2019; 15(6):1453-1456. PubMed ID: 29781761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prospect for vaccines to prevent Clostridium difficile infection.
    Ghose C; Kelly CP
    Infect Dis Clin North Am; 2015 Mar; 29(1):145-62. PubMed ID: 25677708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and management of Clostridium difficile infection.
    Korman TM
    Semin Respir Crit Care Med; 2015 Feb; 36(1):31-43. PubMed ID: 25643269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Existing and investigational therapies for the treatment of Clostridium difficile infection: A focus on narrow spectrum, microbiota-sparing agents.
    Maxwell-Scott HG; Goldenberg SD
    Med Mal Infect; 2018 Feb; 48(1):1-9. PubMed ID: 29169816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences of the Fecal Microflora With Clostridium difficile Therapies.
    Louie TJ; Byrne B; Emery J; Ward L; Krulicki W; Nguyen D; Wu K; Cannon K
    Clin Infect Dis; 2015 May; 60 Suppl 2():S91-7. PubMed ID: 25922407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthroughs in the treatment and prevention of Clostridium difficile infection.
    Kociolek LK; Gerding DN
    Nat Rev Gastroenterol Hepatol; 2016 Mar; 13(3):150-60. PubMed ID: 26860266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of Clostridium difficile infection.
    Dupont HL
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Chicken IgY Specific to
    Pizarro-Guajardo M; Díaz-González F; Álvarez-Lobos M; Paredes-Sabja D
    Front Cell Infect Microbiol; 2017; 7():365. PubMed ID: 28856119
    [No Abstract]   [Full Text] [Related]  

  • 19. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines.
    Gerding DN
    Discov Med; 2012 Jan; 13(68):75-83. PubMed ID: 22284786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing downstream Clostridium difficile infections with upstream antibiotic management.
    Malkan AD; Scholand SJ
    Med Hypotheses; 2012 Jan; 78(1):136-7. PubMed ID: 22079651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.